Anesiva ends 2009 with a bankruptcy petition

Anesiva didn't make it intact into the new year. The South San Francisco-based company announced on New Year's Eve that it couldn't complete a planned merger with Arcion Therapeutics and instead would cease operations and file for bankruptcy.

The merger pact came with some tough provisions, including a requirement that Anesiva gin $20 million from a stock sale and clean up some debts. In a statement, the developer says it was unable to meet the conditions laid out in the merger deal.

The bankruptcy notice caps a long, painful struggle for Anesiva, which announced it was cutting jobs in the fall of 2008. Later, manufacturing problems forced the company to halt production of its Zingo pain patch, and last spring auditors issued a going-concern notice to the company, saying Anesiva didn't have enough funds to complete development of its only drug, Adlea. 

- check out the Anesiva release

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.